Terremoto Biosciences, a clinical-stage biotechnology company focused on highly selective small molecule therapies, announced it has closed a $108 million Series C financing to advance its pipeline targeting cancer and rare diseases. The round included new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, alongside existing backers OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.
The company will use the proceeds to advance its lead AKT1-selective inhibitor programs through Phase 1 clinical development, targeting both oncology indications and hereditary hemorrhagic telangiectasia, a rare inherited bleeding disorder with no approved therapies.
Terremoto’s lead oncology candidate, TER-2013, is currently in Phase 1 trials for solid tumors associated with genetic alterations in PIK3CA, AKT, or PTEN, which are implicated in a significant portion of cancers, including a large share of hormone receptor-positive breast cancer cases. The company is also progressing TER-4480, a program for hereditary hemorrhagic telangiectasia, which is expected to enter clinical development later this year.
The company’s approach focuses on selectively targeting the AKT1 isoform, which has been identified as a primary driver of disease progression, while avoiding inhibition of related isoforms linked to adverse side effects. By leveraging advanced medicinal chemistry, Terremoto aims to deliver more effective treatments with improved tolerability compared to existing therapies targeting the broader PI3K/AKT pathway.
The financing supports continued advancement of the company’s platform as it seeks to develop next-generation targeted therapies for patients with significant unmet medical needs.
KEY QUOTE:
“Proceeds from this financing enable us to advance our lead AKT1-selective inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia. We are grateful for the support from new and existing investors as we work to unlock the full potential of selective AKT1 inhibition and bring more effective and better tolerated treatment options to patients with significant unmet need.”
Charles Baum, M.D., Ph.D., Chief Executive Officer, Terremoto Biosciences
